<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04864418</url>
  </required_header>
  <id_info>
    <org_study_id>PN-021-11</org_study_id>
    <nct_id>NCT04864418</nct_id>
  </id_info>
  <brief_title>AST-021p Study in Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety, Tolerability and Optimal Immunogenic Dose of Therapeutic Cancer Vaccine (AST-021p) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aston Sci. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aston Sci. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and optimal Immunogenic&#xD;
      dose of therapeutic cancer vaccine (AST-021p) in patients With advanced solid tumors&#xD;
&#xD;
      A phase 1 study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recurrent or advanced solid cancer patients without applicable standard treatments will be&#xD;
      included in the 4 dose groups (4 cohort groups- 1.2mg, 2.4mg,3.6mg and 4.8mg) of AST-021p.&#xD;
      Participants in each cohort group will be treated 3 times in each dose (3 priming&#xD;
      immunications)&#xD;
&#xD;
      This study will apply a modified 3+3 design for dose-escalation.&#xD;
&#xD;
      1 participant will be registered in the lowest dose cohort group(1.2mg) and when the safety&#xD;
      and tolerance of the AST-021p(1.2mg) are identified in the the first group, dose will be&#xD;
      increased sequentially and accordingly, the safety and tolerance will be assessed for six&#xD;
      participants in the other cohort groups (group2(2.4mg), group3(3.6mg) and group4(4.8mg)).&#xD;
&#xD;
      Participants receiving priming immunization only will be assessed up to End of Treatment(EOT)&#xD;
      and participants who recive boosting immunization will be evaluated until the end of&#xD;
      study(EOS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by AST-021p</measure>
    <time_frame>6weeks after AST-021p administration in each cohort group</time_frame>
    <description>After AST-021p administration in patients with advance solid tumor, safety and tolerance are assessed for each dose group(1.2mg,2.4mg, 3.6mg &amp;4.8mg)&#xD;
Safety and tolerance evaluation variables :&#xD;
1)adverse events 2) Vital signs 3)Physical examination 4) ECOG performance evaluation 5)ECG examination 6)Laboratory examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity assessment</measure>
    <time_frame>8weeks after ASP-021p administration (Priming immunization case) or 20weeks after ASP-021p(Priming immunization and Boosting immunization case)</time_frame>
    <description>ASP-021p specific IFN-γ ELISpot(Interferon Gamma Enzyme-linked immunospot) test results and ASP-021p4 &amp; ASP-021p5 specific IFN-γ ELISpot ( spots/250,000 Tcell of pre ASP-021p and post ASP-021p)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response assessment</measure>
    <time_frame>Overall study period approximately up to 5months</time_frame>
    <description>Disease control rate (%), objective response rate(%) and duration of response (days &amp; weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival rate</measure>
    <time_frame>Overall study period approximately up to 5months</time_frame>
    <description>PFS rate (%) at End of Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival rate</measure>
    <time_frame>Overall study period approximately up to 5months</time_frame>
    <description>OS rate (%) at End of study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">19</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort group of AST-021p for dose-escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cohort groups for AST- 021p administration:&#xD;
Group 1) 1.2mg AST-021p, Montanide ISA 51 VG and rhuGM-CSF&#xD;
Group 2) 2.4mg AST-021p, Montanide ISA 51 VG and rhuGM-CSF&#xD;
Group 3) 3.6mg AST-021p, Montanide ISA 51 VG and rhuGM-CSF&#xD;
Group 4) 4.8mg AST- 021p, Montanide ISA 51 VG and rhuGM-CSF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AST-021p</intervention_name>
    <description>3 priming immunization (2weeks x3) in 4 cohort groups (1.2mg, 2.4mg, 3.6mg and 4.8mg AST-021p) if possible, 3 boosting immunization (4weeks x 3) in cohort groups after priming immunization</description>
    <arm_group_label>Cohort group of AST-021p for dose-escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  has recurrent or metastatic solid cancer that has been proven histologically or&#xD;
             cytologically and cannot be treated with surgery or radiotherapy for the purpos of&#xD;
             complete remission&#xD;
&#xD;
          -  does not have a standard treatment that can be applied clinically according to the&#xD;
             investigator's judgment&#xD;
&#xD;
          -  has an expected life expectancy of more than 6 months&#xD;
&#xD;
          -  adults aged 19 or older based on screening day&#xD;
&#xD;
          -  ECOG performance status : 0~1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a history of hypersensitivity or other contraindications to rhGM-CSF and Montanide&#xD;
             ISA 51 VG&#xD;
&#xD;
          -  Has a history of other primary malignant tumor&#xD;
&#xD;
          -  Has autoimmune diseases or inflammatory diseases&#xD;
&#xD;
          -  Has a history of active primary immunodeficiency disease&#xD;
&#xD;
          -  Has active infection including tuberculosis, hepatitis B, hepatitis C or human&#xD;
             immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Is pregnant or breastfeeding or expecting to conceive children&#xD;
&#xD;
          -  has a history of immune suppression therapy ≤4 weeks prior to the screening day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyong Hwa Park, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyunwon Shin, MD. PhD</last_name>
    <phone>+82-2-2038-2347</phone>
    <email>hyunwon.shin@astonsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aston Science</last_name>
    <email>astonsci@astonsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Guro-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eun-joo Kang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyong Hwa Park, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer vaccine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

